# South America Allergy Immunotherapy Market > South America Allergy Immunotherapy Market Research Report: By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies), By Patient Type (Pediatric, Adult, Geriatric) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.43% - **2018:** $ 532 Million - **2024:** $ 283 Million - **2035:** $ 762.7 Million - **Key Players:** Allergopharma (BR), Aimmune Therapeutics (BR), Stallergenes Greer (BR), Meda Pharma (BR), Boehringer Ingelheim (BR), Merck KGaA (BR), Novartis (BR), Sanofi (BR), Bayer (BR) **Report ID:** MRFR/HC/54530-HCR · **Pages:** 200 · **Author:** Nidhi Mandole · **Last Updated:** May 12, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-allergy-immunotherapy-market-56296 --- ## Market Summary **South America Allergy Immunotherapy Market Overview****:** **As per MRFR analysis, the South America Allergy Immunotherapy Market Size was estimated at 532 (USD Million) in 2023. The South America Allergy Immunotherapy Market Industry is expected to grow from 571(USD Million) in 2024 to 1,250 (USD Million) by 2035. The South America Allergy Immunotherapy Market CAGR (growth rate) is expected to be around 7.383% during the forecast period (2025 - 2035).** **Key South America Allergy Immunotherapy Market Trends Highlighted** The South America Allergy Immunotherapy Market is currently undergoing a variety of substantial market trends, which are being driven by the increasing prevalence of allergies and the increased awareness of available treatments. The surge in allergic conditions such as asthma, allergic rhinitis, and atopic dermatitis has been influenced by a growing population that is becoming increasingly susceptible to allergies as a result of urbanization, lifestyle changes, and environmental factors. These factors are key market drivers. Healthcare providers are expanding immunotherapy treatment options as a viable solution in response to the increasing prevalence of allergic disorders among children and adults in countries such as Brazil and Argentina. The market offers a plethora of opportunities for exploration, such as the integration of digital health solutions that can simplify the monitoring of allergen exposure and patient follow-up. Additionally, the development of innovative therapies that specifically target the allergens that are prevalent in the region, such as pollen and dust mites, can be facilitated by collaboration between pharmaceutical companies, research institutions, and healthcare providers. The heightened emphasis on personalized medicine also creates opportunities for immunotherapy treatments that are specifically designed for populations in South America based on genetic factors and patient profiles. Sublingual immunotherapy is experiencing a surge in popularity as a result of its convenience and enhanced patient adherence, as evidenced by recent trends.Additionally, health authorities in countries such as Chile and Colombia are conducting ongoing educational initiatives to increase awareness of allergy treatments, thereby cultivating a more well-informed patient population. Patients are at an increased risk of seeking out immunotherapy options as healthcare access improves, which in turn stimulates market growth. In general, these factors are influencing the South American Allergy Immunotherapy Market as it adjusts to accommodate the changing demands of the populace. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America Allergy Immunotherapy Market Drivers** Increase in Allergy Incidence in South America The South America Allergy Immunotherapy Market Industry is experiencing substantial growth due to the rising incidence of allergic diseases in the region. Studies from the Pan American Health Organization indicate that allergic rhinitis affects approximately 20% of the population in South America, significantly driving the demand for immunotherapy. Furthermore, the rise in urbanization and changing lifestyles have been correlated with a 30% increase in the prevalence of respiratory allergies over the last decade.This urban shift is compounded by factors such as increased pollution levels from urban development and industrial activities, which directly contribute to elevated allergen exposure. Established organizations like the Brazilian Society of Allergy and Immunology (SBAI) are actively promoting awareness of allergy management, which underscores the importance of immunotherapy. The emphasis on allergy awareness and treatment options in South America signifies a robust market growth potential driven by an increasing focus on addressing allergic conditions. Advancements in Allergy Immunotherapy Technologies Technological advancements in allergy immunotherapy are significantly contributing to the growth of the South America Allergy Immunotherapy Market Industry. Recent developments in sublingual immunotherapy and new delivery mechanisms have made treatment more convenient and effective for patients. For instance, a study published by the Latin American Society of Allergy, Asthma, and Immunology noted a 25% improvement in treatment adherence due to easier administration forms.Additionally, patent filings for novel immunotherapy solutions have surged in South America, indicating increased Research and Development (R&D) activity. This innovation facilitates personalized treatment plans and enhances patient outcomes, which not only attracts healthcare providers but also instills confidence in patients, thereby contributing to market expansion. Government Initiatives and Policies Supporting Allergy Treatments Government initiatives across South America are playing a pivotal role in enhancing the accessibility and availability of allergy immunotherapy treatments. Various national health policies have been introduced to promote better allergy management, including subsidies for immunotherapy medications and educational programs aimed at healthcare professionals. For example, the Argentine government's health programs have increased funding for allergy research, leading to improved treatment options.Moreover, collaborative efforts between government bodies and health organizations, such as the Ministry of Health in Colombia, are resulting in increased public awareness regarding allergies. The commitment of governments to allocate resources and promote strategies for allergy treatment is creating a favorable environment for the South America Allergy Immunotherapy Market Industry. **South America Allergy Immunotherapy Market Segment Insights****:** **Allergy Immunotherapy Market Type Insights****** **** The South America Allergy Immunotherapy Market is gaining attention due to its critical role in treating various allergic conditions, which are increasingly prevalent across the region. Within this market, the Type segment encompasses three primary categories: Subcutaneous Immunotherapy, Sublingual Immunotherapy, and Oral Immunotherapy, each contributing to the landscape of allergy treatments. Subcutaneous Immunotherapy, often recognized for its effectiveness, is a traditional approach that involves allergy shots administered regularly, resulting in a gradual desensitization to allergens. This method remains significant as it is widely accepted and has a robust history of successful outcomes among patients, thus establishing its dominance in the market.Sublingual Immunotherapy, on the other hand, offers convenience and accessibility, allowing patients to place allergen extracts under the tongue rather than undergoing injections. This non-invasive approach is popular among patients who prefer an alternative to traditional shots, making it a growing segment in the South America Allergy Immunotherapy Market. Its ease of use has resulted in increasing demand, particularly among children and those apprehensive about needles. Moreover, Sublingual Immunotherapy aligns with the shifting trends toward home-based treatment options, reflecting a broader pattern in healthcare toward patient-centered care.Oral Immunotherapy presents a novel treatment strategy as well, utilizing food allergens to build tolerance through gradual exposure. This approach is particularly relevant in addressing food allergies, which are rising in prevalence across South America. By focusing on oral administration, this method not only increases patient adherence but also enhances the quality of life for individuals with serious allergic reactions to foods. The innovation in Oral Immunotherapy signifies a shift in how allergies are managed, showcasing the potential for enhanced therapeutic options.Together, these segments not only highlight the versatility of Allergy Immunotherapy but also underscore the anticipated growth in the market, fueled by increasing rates of allergy diagnoses across South America. As healthcare systems evolve and adapt to the needs of patients, the Type segment is poised to benefit significantly while addressing growing concerns regarding allergies. These trends are observed in countries across South America, where public health initiatives are increasingly focused on allergy awareness and treatment, thereby creating opportunities for each segment within the South America Allergy Immunotherapy Market to expand and innovate. The unique characteristics and benefits of each type provide patients in the region with diversified options for allergy management, enabling them to select therapies that cater to their preferences and lifestyles. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Allergy Immunotherapy Market Product Insights****** **** The South America Allergy Immunotherapy Market is experiencing significant growth, with evolving trends and increased awareness surrounding allergies and their treatments. Within the Product segment, Allergen Extracts have gained prominence as they provide targeted treatment options for allergy sufferers, enabling effective desensitization. Conventional Immunotherapy remains an essential approach, leveraging established methodologies to manage a variety of allergic conditions, while Biologics offer innovative pathways, addressing more severe cases and improving patient outcomes.The growing incidence of allergies in South America has fueled the demand for all these treatment modalities, driven by a greater emphasis on patient-centered care and personalized medicine. The complexity of allergies, coupled with lifestyle changes, presents both challenges and opportunities for the South America Allergy Immunotherapy Market, creating a robust landscape for product development and increasing choices for patients seeking relief from allergy symptoms. Stakeholders are keenly observing shifts in treatment preferences, with a focus on how advancements in allergen extraction and biologics are likely to shape the future landscape of the industry in this region.The increased adoption of these therapies provides a pathway for increased market growth, reflecting a commitment to enhancing the quality of life for those affected by allergies across South America. **Allergy Immunotherapy Market Indication Insights****** **** The South America Allergy Immunotherapy Market is categorized primarily by indication, encompassing various allergic conditions such as Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies. Among these, Allergic Rhinitis represents a dominant share, given the region's high prevalence of pollen and other allergens due to its diverse climate and vegetation. This condition significantly affects the quality of life for many individuals, thereby driving the demand for effective immunotherapy solutions. Allergic Asthma is another critical segment, with increased urbanization and pollution contributing to rising respiratory issues.Atopic Dermatitis continues to gain attention due to its impact on skin health, affecting both children and adults. Meanwhile, Food Allergies remain a concerning area, with rising reports of allergic reactions prompting consumers to seek safer dietary options. The growth in awareness regarding these allergies and the effectiveness of immunotherapy is fostering innovation and the development of targeted therapies, propelling the overall market forward. Enhanced healthcare initiatives and investments in Research and Development within South America are also vital for addressing these allergy-related challenges, indicating significant opportunities for growth and advancement in the Allergy Immunotherapy Market. **Allergy Immunotherapy Market Patient Type Insights****** **** The South America Allergy Immunotherapy Market is strategically categorized by Patient Type, encompassing Pediatric, Adult, and Geriatric populations, which collectively play a pivotal role in market dynamics. The Pediatric segment is particularly significant due to the rising prevalence of allergic conditions in children, driving demand for effective allergy management solutions. Similarly, the Adult population constitutes a substantial section, often reflecting the increased experience of allergy symptoms and the need for treatment as they age, demonstrating the importance of tailored immunotherapy.Moreover, the Geriatric group is becoming increasingly important as aging populations in countries like Brazil and Argentina experience higher rates of both allergies and comorbidities that complicate treatment plans. Understanding these demographic trends is essential for developing effective therapies and optimizing market strategies, as each patient group presents unique needs and challenges. Furthermore, market trends indicate a growing awareness and acceptance of immunotherapy across all age groups, offering significant opportunities for growth in patient-specific treatment programs and enhancing the overall South America Allergy Immunotherapy Market statistics. **Allergy Immunotherapy Market Regional Insights****** **** The South America Allergy Immunotherapy Market is multifaceted, showcasing considerable promise across various regional divisions, including Brazil, Mexico, Argentina, and the Rest of South America. Brazil holds a dominant position due to its vast population and increasing prevalence of allergic conditions, driving significant investment in healthcare innovations. Mexico is also emerging as a critical player as it grapples with rising allergy cases and improved access to healthcare solutions. Argentina is on a steady path towards growth, spurred by increasing awareness and accessibility of immunotherapy treatments among its population.The Rest of South America represents a crucial part of the market, with diverse demographics and a growing understanding of allergy management that is expected to propel demand within the region. Overall, the South America Allergy Immunotherapy Market segmentation underscores the varied dynamics at play, influenced by local healthcare policies, demographic trends, and the urgency to address allergy-related health challenges. These regional insights collectively illustrate the market's future trajectory, reflecting the importance of tailored approaches to meet the unique needs of each country's population and healthcare systems. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America Allergy Immunotherapy Market Key Players and Competitive Insights****:** The South America Allergy Immunotherapy Market has been experiencing significant growth as environmental factors and lifestyle changes contribute to increased allergy prevalence across the region. Competitive insights reveal a robust landscape with a variety of stakeholders, including established companies, local manufacturers, and research institutions focusing on innovative solutions to address allergy-related health issues. The market consists of both sublingual and injectable immunotherapy approaches, catering to a diverse range of allergens. Companies are investing in research and development activities to enhance product efficacy and expand their offerings, with a focus on patient-centric therapies. Moreover, collaborations with healthcare providers and regulatory bodies have become essential for navigating the complex market dynamics, providing a path for sustained growth and development within this sector.Stallergenes Greer has established a significant presence in the South America Allergy Immunotherapy Market, known for its strong portfolio of allergen immunotherapy products. The company holds a competitive edge due to its focus on sublingual immunotherapy, which has gained popularity for its ease of administration and enhanced patient compliance. Stallergenes Greer has built robust relationships with healthcare professionals and local distributors, facilitating widespread access to its products across various countries in South America. The company leverages its extensive clinical research, which underscores the effectiveness and safety of its allergy treatments, reinforcing its market position. With a strong commitment to patient education and support programs, Stallergenes Greer continues to solidify its reputation and reliability among allergists and patients alike.Anergis has made notable strides in the South America Allergy Immunotherapy Market, particularly with its innovative approaches to handling various allergies through its specific immunotherapy products. The company specializes in the development of its allergy vaccine platforms, which aim to provide effective and long-lasting relief for allergy sufferers. Anergis benefits from a well-structured research and development framework, allowing for rapid advancements in product offerings. With its ventures focusing on strategic partnerships and collaborations within the region, Anergis is positioning itself strongly against competitors. Their key products emphasize the use of proprietary adjuvants that enhance immunogenicity, thereby offering superior therapeutic options. As the company continues to expand its market presence through potential mergers and acquisitions, its focus on delivering cutting-edge therapies ensures that Anergis remains a prominent player in addressing the rising demand for allergy treatments in South America. **Key Companies in the South America Allergy Immunotherapy Market Include:** Stallergenes Greer Anergis ImmunoCap Aimmune Therapeutics Boehringer Ingelheim Thermo Fisher Scientific Mylan Novartis ALK Technologies Merck KGaA HollisterStier Allergy Datapharm Alk Abello **South America Allergy Immunotherapy Market Industry Developments** _The South America Allergy Immunotherapy Market has recently seen significant developments, influenced by companies such as Stallergenes Greer, Anergis, ImmunoCap, Aimmune Therapeutics, Boehringer Ingelheim, Thermo Fisher Scientific, Mylan, Novartis, ALK Technologies, Merck KGaA, HollisterStier Allergy, Datapharm, and Alk Abello. In May 2023, Stallergenes Greer announced an expansion of its operations in Brazil to enhance its production and distribution capabilities. Additionally, in August 2023, Boehringer Ingelheim launched a new line of allergy immunotherapy products in Argentina, responding to the rising prevalence of allergic conditions in the region. Over the past two years, the market has also witnessed growth, attributed to increased investments and collaborations among the key players. For instance, Aimmune Therapeutics and Merck KGaA revealed a partnership in early 2022 aimed at advancing Research and Development for allergic food therapies in Brazil. The Allergy Immunotherapy Market is projected to expand due to rising awareness of allergies and overall healthcare investment in South America. These developments are indicative of the dynamic and evolving landscape of the allergy treatment sector across the continent._ **South America Allergy Immunotherapy Market Segmentation Insights** **Allergy Immunotherapy Market Type****Outlook** **Subcutaneous Immunotherapy** **Sublingual Immunotherapy** **Oral Immunotherapy** **Allergy Immunotherapy Market Product****Outlook** **Allergen Extracts** **Conventional Immunotherapy** **Biologics** **Allergy Immunotherapy Market Indication****Outlook** **Allergic Rhinitis** **Allergic Asthma** **Atopic Dermatitis** **Food Allergies** **Allergy Immunotherapy Market Patient Type****Outlook** **Pediatric** **Adult** **Geriatric** **Allergy Immunotherapy Market Regional****Outlook** **Brazil** **Mexico** **Argentina** **Rest of South America** **** ## Market Drivers ### Growing Investment in Healthcare The surge in investment in healthcare infrastructure across South America is likely to bolster the South America [Allergy Immunotherapy](https://www.marketresearchfuture.com/reports/allergy-immunotherapy-market-1517) Market. As countries like Argentina and Chile allocate more resources to healthcare, the availability of advanced treatment options, including immunotherapy, is expected to improve. This investment is not only aimed at expanding healthcare facilities but also at enhancing research and development in allergy treatments. Consequently, the South America Allergy Immunotherapy Market may witness an influx of innovative therapies and improved patient care. The focus on healthcare investment suggests a promising future for the market, as it aligns with the increasing demand for effective allergy management solutions. ### Government Initiatives and Policies Government initiatives aimed at improving healthcare access and allergy management are likely to play a crucial role in the South America Allergy Immunotherapy Market. Various South American countries have implemented policies to enhance healthcare infrastructure and promote allergy awareness. For instance, Brazil has introduced programs to support allergy research and treatment accessibility, which may lead to increased adoption of immunotherapy. Additionally, regulatory bodies are working to streamline the approval process for new allergy treatments, thereby encouraging innovation in the market. These supportive measures from governments could potentially enhance the growth trajectory of the South America Allergy Immunotherapy Market, as they facilitate better access to effective treatment options for patients. ### Rising Awareness of Allergy Treatments The increasing awareness regarding allergy treatments among the South American population appears to be a significant driver for the South America Allergy Immunotherapy Market. Educational campaigns and initiatives by healthcare organizations have contributed to a better understanding of allergies and their management. This heightened awareness is likely to lead to a greater demand for immunotherapy options, as patients seek effective solutions for their allergic conditions. Furthermore, the prevalence of allergic diseases, such as [allergic rhinitis](https://www.marketresearchfuture.com/reports/allergic-rhinitis-market-1547) and asthma, has been on the rise, prompting healthcare providers to recommend immunotherapy as a viable treatment option. As a result, the South America Allergy Immunotherapy Market is expected to experience growth, driven by informed patients actively seeking treatment alternatives. ### Technological Innovations in Immunotherapy Technological advancements in immunotherapy delivery methods are poised to transform the South America Allergy Immunotherapy Market. Innovations such as sublingual immunotherapy and advanced allergen extracts are becoming more prevalent, offering patients more convenient and effective treatment options. These advancements are likely to enhance patient compliance and satisfaction, as they provide alternatives to traditional injection-based therapies. Moreover, the integration of digital health technologies, such as mobile applications for monitoring treatment progress, may further improve patient engagement in their allergy management. As these technologies continue to evolve, the South America Allergy Immunotherapy Market is expected to benefit from increased adoption and a broader range of treatment modalities. ### Rising Incidence of Allergic Rhinitis and Asthma The rising incidence of allergic rhinitis and asthma in South America is a critical driver for the South America Allergy Immunotherapy Market. According to recent health reports, the prevalence of these conditions has been steadily increasing, affecting a significant portion of the population. This trend is likely to create a growing demand for effective treatment options, including immunotherapy. As healthcare providers recognize the need for long-term solutions to manage these chronic conditions, immunotherapy is being recommended more frequently. Consequently, the South America Allergy Immunotherapy Market is expected to expand, driven by the urgent need for effective management strategies for allergic diseases. ## Future Outlook The South America Allergy Immunotherapy Market is projected to grow at a 9.43% CAGR from 2024 to 2035, driven by increasing allergy prevalence and advancements in treatment technologies. **New opportunities:** - Expansion of digital health platforms for remote patient monitoring Development of personalized immunotherapy solutions Strategic partnerships with healthcare providers for integrated care models By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in allergy treatment solutions. ## Segment Insights ### By Application: Allergic Rhinitis (Largest) vs. Allergic Asthma (Fastest-Growing) In the South America Allergy Immunotherapy Market, the distribution of market share reflects a notable dominance in the allergic rhinitis segment, which accounts for a significant portion of the overall industry. This can be attributed to the high prevalence of seasonal and perennial allergies in the region, coupled with increased awareness and diagnosis, leading to higher demand for immunotherapy treatments. Conversely, the allergic asthma segment, while smaller in market share, is experiencing rapid growth as more individuals seek effective allergy management solutions, fueled by rising pollution levels and urbanization. Growth trends in the allergy immunotherapy market are largely driven by the increasing allergies prevalence and changing lifestyles. The emergence of advanced treatment options and growing investment in allergy research also play a crucial role in catalyzing the growth of both allergic rhinitis and allergic asthma segments. Invalidated by environmental factors, such as dust and pollen exposure, asthmatics represent a newly identified and potentially underserved population that is increasingly turning to immunotherapy to manage their condition more effectively. Allergic Rhinitis (Dominant) vs. Food Allergies (Emerging) Allergic rhinitis continues to be the dominant segment in the South America Allergy Immunotherapy Market, primarily due to its high prevalence and the impact of environmental factors. Patients suffering from allergic rhinitis experience symptoms such as sneezing, nasal congestion, and itchy eyes, which significantly affect their quality of life. This widespread condition has made it a focal point for healthcare providers and pharmaceutical companies. Conversely, food allergies represent an emerging segment, gaining attention over the past few years. As awareness of food allergy prevalence rises, particularly among children, there is an increasing demand for tailored immunotherapy solutions. This shift is catalyzed by both new research findings and policy developments aimed at improving food allergy management, marking food allergies as a vital area for future growth. ### By Type of Immunotherapy: Subcutaneous Immunotherapy (Largest) vs. Sublingual Immunotherapy (Fastest-Growing) In the South America Allergy Immunotherapy Market, Subcutaneous Immunotherapy holds the largest market share among the various types, owing to its long-standing efficacy and acceptance among healthcare professionals. In contrast, Sublingual Immunotherapy is rapidly gaining traction, particularly among patients seeking more convenient options for allergy management. As a result, both segments play a crucial role in the overall landscape, appealing to different consumer preferences and treatment needs. Growth trends in this sector reflect a growing preference for less invasive treatment methods, with an increasing number of patients opting for Sublingual Immunotherapy due to its ease of administration and safety profile. Factors such as rising allergic conditions and a broader acceptance of immunotherapy contribute to the strengthening of both Subcutaneous and Sublingual segments in South America. National initiatives promoting allergy awareness further bolster market growth. Subcutaneous Immunotherapy (Dominant) vs. Sublingual Immunotherapy (Emerging) Subcutaneous Immunotherapy is the dominant approach in the South American market, primarily due to its efficacy and comprehensive clinical history. This method involves administering allergens via injection, which stimulates the immune system to build tolerance. Patients benefit from structured dose escalation processes, leading to lasting relief from allergies. Conversely, Sublingual Immunotherapy is emerging rapidly, driven by consumer demand for non-invasive, self-administrable options. It is taken under the tongue, allowing patients to use it in the comfort of their homes. This formulation eliminates the need for needles, making it increasingly appealing, especially among children and those averse to injections. As healthcare systems evolve, both types will likely coexist, serving diverse patient needs. ### By Patient Demographics: Pediatric Patients (Largest) vs. Adult Patients (Fastest-Growing) In the South America Allergy Immunotherapy Market, the market share distribution among patient demographics reveals that pediatric patients constitute the largest segment, accounting for a significant portion of overall treatments. This is largely due to the rising incidence of allergies in children and increased awareness about immunotherapy as an effective treatment option. In contrast, adult patients represent the fastest-growing segment, spurred by an increase in allergy diagnoses and shifting lifestyle factors that have made adult populations more susceptible to allergic reactions. Pediatric Patients (Dominant) vs. Adult Patients (Emerging) Pediatric patients dominate the South America Allergy Immunotherapy Market due to their vulnerability to a variety of allergic conditions, including asthma, hay fever, and food allergies. This segment's growth is driven by parental awareness of the long-term benefits of immunotherapy for children, leading to increased demand for tailored treatments. On the other hand, adult patients represent an emerging segment as they experience heightened allergic reactions influenced by environmental factors and urbanization. With adults being more inclined to seek medical intervention, the trend is moving towards expanded treatment options that cater specifically to adult allergy sufferers, thus indicating an evolving market landscape. ### By Treatment Duration: Long-term Treatment (Largest) vs. Induction Treatment (Fastest-Growing) In the South America Allergy Immunotherapy Market, the treatment duration segment is characterized by a notable distribution among various values. Long-term treatment stands out as the largest segment, capturing significant preference among patients and healthcare providers. This segment emphasizes sustained therapy over time, leading to more durable allergy relief and improved quality of life. Conversely, induction treatment is emerging as the fastest-growing segment, driven by increasing awareness and acceptance of rapid intervention protocols that enhance therapeutic efficacy for patients needing quick relief from symptoms. Long-term Treatment (Dominant) vs. Induction Treatment (Emerging) Long-term treatment remains a dominant strategy within the South America Allergy Immunotherapy Market due to its proven track record of improving patient outcomes over extended periods. It focuses on desensitizing patients through gradual exposure to allergens, leading to a more stable immune response. On the other hand, induction treatment is gaining traction as an emerging approach that accelerates the benefits of immunotherapy. This method appeals to patients seeking immediate relief from severe allergic reactions and aligns well with modern healthcare's shift towards more flexible treatment regimens. Both segments cater to the growing demand for effective allergy management solutions in the region. ## Regional Market Share Analysis ### Brazil : Strong Demand and Growth Drivers Brazil holds a dominant position in the South American allergy immunotherapy market, accounting for 120.0 million, representing a significant market share. Key growth drivers include increasing allergic conditions, heightened awareness of immunotherapy benefits, and supportive government initiatives promoting healthcare access. Regulatory policies are evolving to streamline the approval process for new therapies, while infrastructure improvements in healthcare facilities enhance service delivery and patient access. ### Mexico : Increasing Awareness and Accessibility Mexico's allergy immunotherapy market is valued at 50.0 million, reflecting a growing demand driven by rising allergy prevalence and increasing public awareness. The government is implementing initiatives to improve healthcare access, which is crucial for expanding immunotherapy services. Regulatory frameworks are becoming more favorable, encouraging investments in the sector, while urbanization and healthcare infrastructure development are enhancing service delivery. ### Argentina : Regulatory Support and Market Expansion Argentina's market for allergy immunotherapy is valued at 80.0 million, showcasing steady growth. Key drivers include a rising incidence of allergic diseases and government support for innovative treatment options. Regulatory bodies are actively working to facilitate the introduction of new therapies, while healthcare infrastructure improvements are making treatments more accessible. The demand for personalized medicine is also on the rise, influencing consumption patterns. ### Rest of South America : Varied Demand Across Regions The Rest of South America represents a smaller segment of the allergy immunotherapy market, valued at 33.0 million. Growth is driven by varying levels of awareness and healthcare access across countries. Regulatory environments differ significantly, impacting market dynamics. Urban centers like Santiago and Lima are key markets, but challenges such as limited infrastructure and varying healthcare policies hinder growth. Local players are adapting to these conditions to capture market share. ## Competitive Benchmarking The South America Allergy Immunotherapy Market is currently characterized by a dynamic competitive landscape, driven by increasing prevalence of allergic conditions and a growing awareness of immunotherapy as a viable treatment option. Key players such as Allergopharma (BR), Aimmune Therapeutics (BR), and Stallergenes Greer (BR) are strategically positioned to leverage innovation and regional expansion to enhance their market presence. These companies are focusing on developing advanced therapies and expanding their distribution networks, which collectively shapes a competitive environment that is both collaborative and competitive, fostering a climate of continuous improvement and adaptation. In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market structure appears moderately fragmented, with several players vying for market share. This fragmentation allows for a diverse range of products and services, but also necessitates strategic partnerships and collaborations among key players to optimize resources and enhance market reach. In January 2026, Allergopharma (BR) announced the launch of a new line of sublingual immunotherapy products aimed at addressing specific regional allergies prevalent in South America. This strategic move is significant as it not only diversifies their product portfolio but also demonstrates a commitment to localized solutions that cater to the unique needs of the population, potentially increasing their market share in a competitive landscape. In December 2025, Aimmune Therapeutics (BR) entered into a partnership with a local biotechnology firm to co-develop a novel immunotherapy treatment targeting peanut allergies. This collaboration is indicative of a broader trend towards strategic alliances that enhance research capabilities and expedite the development of innovative therapies, thereby positioning Aimmune Therapeutics as a leader in addressing critical health issues in the region. In November 2025, Stallergenes Greer (BR) expanded its distribution network by partnering with regional pharmacies to improve accessibility to its immunotherapy products. This strategic action is crucial as it not only enhances customer reach but also aligns with the growing trend of patient-centric approaches in healthcare, ensuring that therapies are readily available to those in need. As of February 2026, current competitive trends in the market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in product development and patient management. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, which are likely to become the cornerstones of success in this market. ## Recent News & Developments _The South America Allergy Immunotherapy Market has recently seen significant developments, influenced by companies such as Stallergenes Greer, Anergis, ImmunoCap, Aimmune Therapeutics, Boehringer Ingelheim, Thermo Fisher Scientific, Mylan, Novartis, ALK Technologies, Merck KGaA, HollisterStier Allergy, Datapharm, and Alk Abello. In May 2023, Stallergenes Greer announced an expansion of its operations in Brazil to enhance its production and distribution capabilities. Additionally, in August 2023, Boehringer Ingelheim launched a new line of allergy immunotherapy products in Argentina, responding to the rising prevalence of allergic conditions in the region. Over the past two years, the market has also witnessed growth, attributed to increased investments and collaborations among the key players. For instance, Aimmune Therapeutics and Merck KGaA revealed a partnership in early 2022 aimed at advancing Research and Development for allergic food therapies in Brazil. The Allergy Immunotherapy Market is projected to expand due to rising awareness of allergies and overall healthcare investment in South America. These developments are indicative of the dynamic and evolving landscape of the [allergy treatment](https://www.marketresearchfuture.com/reports/allergy-treatment-market-11156) sector across the continent._ ## Report Scope Report Scope: | Report Attribute/Metric Source: | Details | | --- | --- | | MARKET SIZE 2018 | 532.0(USD Million) | | MARKET SIZE 2024 | 571.0(USD Million) | | MARKET SIZE 2035 | 1250.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.383% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | MARKET FORECAST PERIOD | 2025 - 2035 | | HISTORICAL DATA | 2019 - 2024 | | MARKET FORECAST UNITS | USD Million | | KEY COMPANIES PROFILED | Stallergenes Greer, Anergis, ImmunoCap, Aimmune Therapeutics, Boehringer Ingelheim, Thermo Fisher Scientific, Mylan, Novartis, ALK Technologies, Merck KGaA, HollisterStier Allergy, Datapharm, Alk Abello | | SEGMENTS COVERED | Type, Product, Indication, Patient Type, Regional | | KEY MARKET OPPORTUNITIES | Rising prevalence of allergies, Increasing awareness of immunotherapy, Growing investment in healthcare, Innovative treatment options emerging, Expansion of distribution networks | | KEY MARKET DYNAMICS | increasing allergic conditions prevalence, growing awareness of immunotherapy, advancements in treatment technologies, supportive regulatory environment, rising healthcare expenditure | | COUNTRIES COVERED | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What is the current valuation of the South America Allergy Immunotherapy Market?** A: As of 2024, the market valuation was 283.0 USD Million. **Q: What is the projected market size for the South America Allergy Immunotherapy Market by 2035?** A: The market is expected to reach a valuation of 762.7 USD Million by 2035. **Q: What is the expected CAGR for the South America Allergy Immunotherapy Market during the forecast period?** A: The market is projected to grow at a CAGR of 9.43% from 2025 to 2035. **Q: Which application segment holds the highest market value in the South America Allergy Immunotherapy Market?** A: The Allergic Rhinitis segment had a valuation of 113.0 USD Million in 2024 and is expected to grow significantly. **Q: How does the market for Sublingual Immunotherapy compare to other types?** A: Sublingual Immunotherapy was valued at 80.0 USD Million in 2024, indicating strong demand compared to other types. **Q: What demographic segment is projected to dominate the South America Allergy Immunotherapy Market?** A: The Adult Patients segment had a valuation of 150.0 USD Million in 2024 and is likely to continue leading the market. **Q: What are the expected trends in treatment duration segments for the market?** A: Long-term Treatment is projected to grow from 85.0 USD Million in 2024 to a higher valuation by 2035. **Q: Which companies are key players in the South America Allergy Immunotherapy Market?** A: Key players include Allergopharma, Aimmune Therapeutics, Stallergenes Greer, and Merck KGaA, among others. **Q: What is the market outlook for Food Allergies in the South America Allergy Immunotherapy Market?** A: The Food Allergies segment was valued at 40.0 USD Million in 2024 and is expected to see growth in the coming years. **Q: How does the market for Geriatric Patients compare to other demographics?** A: The Geriatric Patients segment had a valuation of 40.0 USD Million in 2024, indicating a smaller market share compared to Adult Patients. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-allergy-immunotherapy-market-56296*